You are currently viewing Psychedelic Investments Week in Review (28 March 2020)

Psychedelic Investments Week in Review (28 March 2020)

  • Post category:News

We’re taking a look back at this week’s developments in the psychedelics market.

Champignon Brands ($SHRM)

We have two updates on Champignon this week.

On March 27th, 2020, Champignon entered into a definitive agreement to acquire Tassili Life Sciences, who work with various university research institutes to demonstrate the clinical and physiological efficacy of Psilocybin and CBD with regard to post-concussion syndrome, PTSD, and OCD.

Details of this all-share transaction can be found in the press release.

The second piece of news from Champignon is their appointment of Dr. Joseph Gabrielle to their special advisory committee.

Gabrielle is a molecular pharmacological who has received a variety of awards, including a number of “New Investigator Awards” and the Ernst & Young Entrepreneur of the Year in Healthcare title. More information is available in the press release.

MindMed ($MMED)

Earlier this week MindMed announced that it has opened enrolment in a new suite of safety studies for their non-hallucinogenic proprietary molecule: 18-MC. The substance has shown early promise in its potential for mitigating a number of forms of addiction. Read the full press release here.

That’s all for this week. We hope you’re staying safe during these unprecedented times.

If we missed anything, or you’d like to see us write about something, don’t hesitate to let us know.